Clinical trials: Influenza Virus Infection
Influenza
Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers
The aim of the study to assess the safety, reactogenicity, immunogenicity, and efficacy of quadrivalent inactivated subunit influenza vaccine Grippol® Quadri (NPO Petrovax Pharm, LLC, Russia) versus trivalent inactivated…
- Trial name
- NCT03849560
- Testing
- Grippol® Quadri, Grippol® Plus, trivalent (Yamagata lineage), Grippol® Plus, trivalent (Victoria lineage)
- Where
- 3 sites in Russia
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Influenza
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
- Trial name
- NCT01003418
- Testing
- GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar
- Where
- 4 sites in Norway
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Acquired Immunodeficiency Syndrome
Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda
To use a systems biological approach to study the molecular signatures of innate and adaptive responses to vaccination in a HIV infected versus uninfected adult population in Kampala, Uganda.
- Conditions
- HIV, Acquired Immunodeficiency Syndrome, Influenza
- Trial name
- NCT01916759
- Testing
- Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
- Where
- Uganda
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Emory University
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00345462
- Testing
- Trivalent virosomal influenza vaccine
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
HIV
Immunogenicity of MF59-adjuvanted Versus High-dose Influenza Vaccine in People With HIV: a Randomized Clinical Trial
Seasonal influenza causes morbidity in people with impaired immunity, including adults with elder ages and other comorbidities [1].
- Trial name
- NCT07644546
- Testing
- IM
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Influenza
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study.
- Trial name
- NCT01389466
- Testing
- Step 1, Step 2
- Where
- 4 sites in South Korea
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Study to Evaluate an Influenza Vaccine Candidate
The purpose of this study is to evaluate the immune response and safety of influenza vaccine candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
- Trial name
- NCT00321373
- Testing
- Candidate Influenza Vaccine GSK1247446A - 2 different formulations, FluarixTM
- Where
- 17 sites in Finland, Greece
- Volunteers
- 1,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine…
- Trial name
- DRIVE III (NCT07240922)
- Testing
- Live attenuated influenza vaccine, recombinant hemagglutinin influenza vaccine
- Where
- Hong Kong
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
- Trial name
- NCT00695669
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Influenza Vaccination in the Emergency Department
Randomized controlled trial of influenza vaccination versus referral for vaccination in the Emergency department. Is the Emergency Department an effective venue for vaccination for influenza? Does vaccination for influenza in the…
- Trial name
- NCT00822627
- Testing
- Influenza Vaccination, Education and referral
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Safety, Adverse Event Following Immunisation
Safety of RIV4 Versus IIV4 in Pregnant Women
This is a prospective, randomized clinical trial. During the study, pregnant women will be randomized (1:1) to receive RIV4 or IIV4. Vaccines will be administered by licensed providers.
- Conditions
- Safety, Adverse Event Following Immunisation, Birth Outcomes
- Trial name
- NCT03969641
- Testing
- Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19, Influenza
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent…
- Trial name
- COVID-19 (NCT05519839)
- Testing
- qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant
- Where
- 35 sites in Australia, New Zealand
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A when co-administered with the seasonal flu vaccine in adults 19 to 40 years of age.
- Trial name
- NCT00985673
- Testing
- GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV)
- Where
- 7 sites in United States, Canada
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Viral Vaccines
Flu Vaccine Responses in the Setting of Melanoma Treatment
Influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. We are conducting a prospective unblinded study of influenza vaccine recipients.
- Trial name
- NCT03315975
- Testing
- Inactivated influenza vaccine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Infection Viral
Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period
Hospital-Acquired Influenza (HAI) is closely linked to the intensity of influenza in the community. HAI is associated with significant morbidity, mortality and extra costs due to prolonged hospital stay.
- Trial name
- NOSOGRIPPE (NCT05712759)
- Testing
- Influenza-like illness group
- Sponsor
- Hospices Civils de Lyon
Influenza, Pneumonia
Oseltamivir Randomised Controlled Efficacy Trial
Background In preparation for a global influenza pandemic, there is an urgent need for representative data from populations and settings where the pandemic is most likely to arise.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Upper Respiratory Tract Infection
- Trial name
- NCT00707941
- Testing
- Oseltamivir
- Where
- Bangladesh
- Volunteers
- 1,190 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza
Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine
This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
- Trial name
- NCT00283283
- Testing
- Fluzone® (Aventis Pasteur inactivated influenza vaccine)
- Where
- 2 sites in United States
- Volunteers
- 1,316 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Influenza
A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults
This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.
- Trial name
- NCT00851266
- Testing
- V512
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC